• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus. PROPel Mini, a releasing implant for patients undergoing frontal sinus surgery, is a steroid-release implant. VENSure Navigable and Stand-alone balloon is used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach.
Market Cap | 954.159 Million | Shares Outstanding | 33.788 Million | Avg 30-day Volume | 683.958 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.85 |
Price to Revenue | 9.0862 | Debt to Equity | -1.5167 | EBITDA | -156.627 Million |
Price to Book Value | 0.0 | Operating Margin | -143.4117 | Enterprise Value | 1.037 Billion |
Current Ratio | 1.885 | EPS Growth | -1.201 | Quick Ratio | 1.376 |
1 Yr BETA | 0.1423 | 52-week High/Low | 28.25 / 15.92 | Profit Margin | -161.9386 |
Operating Cash Flow Growth | -49.5485 | Free Cash Flow to Firm (FCFF) TTM | -56.398 Million | Free Cash Flow to Equity (FCFE) TTM | -41.521 Million |
Altman Z-Score | -5.8489 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2022-05-13 | 0 | |
MEIER RICHARD A EVP & CHIEF FINANCIAL OFFICER |
|
0 | 2022-05-13 | 0 |
BRODERICK PATRICK A EVP, GC & CORPORATE SECRETARY |
|
0 | 2022-05-13 | 0 |
|
0 | 2022-05-13 | 0 | |
|
0 | 2022-05-13 | 0 | |
WEST THOMAS A. PRESIDENT AND CEO |
|
0 | 2022-05-13 | 0 |
|
0 | 2022-05-13 | 0 | |
|
0 | 2022-05-13 | 0 | |
FERNANDEZ REYNA M CHIEF HUMAN RESOURCE OFFICER |
|
0 | 2022-05-13 | 0 |
|
0 | 2022-05-13 | 0 | |
KOWALSKI CHRISTINE R EVP & CHIEF OPERATING OFFICER |
|
41,042 | 2021-02-04 | 0 |
|
260,961 | 2021-01-19 | 0 | |
CARSCADDEN GWEN R. CHIEF PEOPLE OFFICER |
|
14,790 | 2021-01-04 | 0 |
|
21,049 | 2020-06-04 | 0 | |
BINNEY ROBERT H JR CHIEF COMMERCIAL OFFICER |
|
37,555 | 2020-03-02 | 0 |
LEHMAN DAVID AARON EVP & GENERAL COUNSEL |
|
100,475 | 2020-02-03 | 0 |
|
884,386 | 2019-07-24 | 0 | |
STIMSON SUSAN P CHIEF STRATEGY OFFICER |
|
42,532 | 2019-06-13 | 0 |
HILLEMAN JERYL L CHIEF FINANCIAL OFFICER |
|
43,836 | 2019-05-07 | 0 |
KAUFMAN RICHARD E TECHNICAL ADVISOR |
|
85,280 | 2019-01-01 | 0 |
PARKER DRAKE R. CHIEF BUSINESS OFFICER |
|
17,000 | 2018-01-17 | 0 |
|
8,581 | 2017-06-01 | 0 | |
WOLBECK AMY V.P. REGULATORY AFFAIRS & QLTY |
|
26,634 | 2016-09-06 | 0 |
STAMBAUGH JAMES VP CLINICAL AFFAIRS |
|
20,000 | 2016-09-02 | 0 |
MCKHANN CHAS CHIEF COMMERCIAL OFFICER |
|
55,000 | 2016-01-15 | 0 |
|
1,200,353 | 2015-05-12 | 0 | |
KLEINER PERKINS CAUFIELD & BYERS XI-A LP |
|
No longer subject to file | 2015-05-11 | 0 |
|
No longer subject to file | 2015-05-08 | 0 | |
|
No longer subject to file | 2015-01-19 | 0 | |
|
No longer subject to file | 2015-01-19 | 0 | |
NORWEST VENTURE PARTNERS XI, LP |
|
No longer subject to file | 2014-07-29 | 0 |
|
2,576,966 | 2014-07-29 | 0 | |
|
0 | 2014-07-29 | 0 | |
|
0 | 2014-07-23 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
INTERSECT ENT INC XENT | 2022-05-13 22:15:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 21:45:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 21:15:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 20:45:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 20:15:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 19:45:04 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 19:15:03 UTC | 0.4081 | 0.4119 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 18:45:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 18:15:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 17:45:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 17:15:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 16:45:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 16:15:03 UTC | 0.408 | 0.412 | 650000 |
INTERSECT ENT INC XENT | 2022-05-13 15:45:03 UTC | 0.408 | 0.412 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 15:15:03 UTC | 0.408 | 0.412 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 14:45:03 UTC | 0.4119 | 0.4081 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 14:15:03 UTC | 0.4119 | 0.4081 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 13:45:03 UTC | 0.4119 | 0.4081 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 13:15:03 UTC | 0.4119 | 0.4081 | 450000 |
INTERSECT ENT INC XENT | 2022-05-13 12:45:03 UTC | 0.4119 | 0.4081 | 450000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | XENT | -262.0 shares, $-3104.7 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | XENT | -26.0 shares, $-308.1 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | XENT | -195.0 shares, $-2310.75 | 2020-03-31 | N-PORT |